VivoSeq
Other

Postpartum Hemorrhage

26

Pipeline Programs↗

15

Active Trials↗

11

Companies Involved↗

Postpartum Hemorrhage is an emerging landscape with 26 programs across 11 companies. The most active players are Neurim Pharmaceuticals Ltd., Resolve Therapeutics, GSK. 7 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

25/100

Mech. Concentration

40/100

Completion Rate

92/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1R

Resolve Therapeutics

1 program

Phase 3GSK logo

GSK

1 program

Phase 3Pfizer logo

Pfizer

1 program

ApprovedA

Amring

1 program

ApprovedR

Retrophin

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

76

clinical trials

Completed45 · 59%
Unknown status11 · 14%
Recruiting7 · 9%
Not yet recruiting7 · 9%
Withdrawn4 · 5%
No longer available1 · 1%
Other1 · 1%

Clinical Trials

Trial Activity

76 trials

Prevention of Postpartum Hemorrhage With Tranexamic Acid
Recruiting·IInova Health Care Services·Phase 2·NCT05370820·120 enrolled
Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage
Recruiting·RRenJi Hospital·Phase 4·NCT06754371·276 enrolled
Postpartum Hemorrhage Reduction With Oral Tranexamic Acid: a Clinical Trial
Recruiting·KKarolinska Institutet·Phase 4·NCT06025916·1,000 enrolled
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Recruiting·SStony Brook University·Phase 3·NCT05245227·1,358 enrolled
Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage
Recruiting·MMahidol University·N/A·NCT07278037·648 enrolled
Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery
Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT06333340·160 enrolled
Pharmacokinetics and Pharmacodynamics of Oxytocin in Cesarean Delivery
Recruiting·UUniversity of Chicago·Phase 2·NCT05488457·100 enrolled
Clinical Trial Designed to Assess the Safety and Effectiveness of the KOKO™ Device In Treating Primary Abnormal Postpartum Uterine Bleeding ("APUB") or Hemorrhage ("PPH")
Active, not recruiting·KKOKO Medical Inc.·Preclinical·NCT06452355·72 enrolled
Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH
Not yet recruiting·SSultan Qaboos University·Phase 3·NCT07474077·88 enrolled
Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone
Not yet recruiting·—·N/A·NCT07318467·80 enrolled
Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
Not yet recruiting·SSheba Medical Center·Phase 4·NCT07401524·120 enrolled
Comparison Between Preoperative Vaginal and Postoperative Sublingual Misoprostol for Prevention of Postpartum Hemorrhage During Cesarean Section
Not yet recruiting·—·Phase 3·NCT06765473·400 enrolled
Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention
Not yet recruiting·WWestern Galilee Hospital-Nahariya·N/A·NCT07353281·146 enrolled
Standard Oxytocin Versus High Dose Oxytocin to Control Postpartum Hemorrhage in High Risk Pregnancy During Elective Cesarean Section
Not yet recruiting·—·N/A·NCT06560099·39 enrolled
Randomized Double-Blinded Clinical Trial of Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section
Not yet recruiting·SStony Brook University·Approved·NCT07688512·180 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)